NCT05665361View on ClinicalTrials.gov

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
Interventions
DRUG

Sasanlimab

Sasanlimab will be given (SC on day 1 of every cycle, starting on day 1 (+/- 5 days) of cycle 2).

DRUG

Palbocicilib

Palbociclib will be given PO for 21 days of every 28-day cycle, starting on day 1 of cycle 1.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH